News & Updates

Show Multimedia Only

Long-term odevixibat shows sustained benefits in ALGS

20 Jun 2025 by

Long-term treatment with odevixibat led to sustained improvements in pruritus scores and reductions in serum bile acid (sBA) levels among patients with Alagille syndrome (ALGS), based on a pooled analysis of the phase III ASSERT and ASSERT-EXT studies presented at ESPGHAN 2025.

Long-term odevixibat shows sustained benefits in ALGS

20 Jun 2025

How does finerenone fare among DKD patients in real life?

19 Jun 2025 by

In patients with chronic kidney disease and type 2 diabetes who have not been previously treated with any mineralocorticoid receptor antagonist (MRA), the use of finerenone results in marked reductions in albuminuria, reports a study presented at ERA 2025.

How does finerenone fare among DKD patients in real life?

19 Jun 2025

Abbreviated vs prolonged DAPT: Is shorter better for at-risk patients?

19 Jun 2025

One-month treatment with dual antiplatelet therapy (DAPT) results in similar adverse events and a reduction in total bleeding risk when compared with prolonged DAPT, a study has shown.

Abbreviated vs prolonged DAPT: Is shorter better for at-risk patients?

19 Jun 2025

Semaglutide helps overweight schizophrenia patients on clozapine lose weight safely

19 Jun 2025

For patients with schizophrenia being treated with clozapine who have high BMI, semaglutide delivers weight-loss benefits without affecting psychotic symptoms or altering clozapine concentrations, according to the double-blind, phase II COaST study.

Semaglutide helps overweight schizophrenia patients on clozapine lose weight safely

19 Jun 2025

Sildenafil does not improve perinatal outcomes related to hypoxia during labour

18 Jun 2025

Treatment with sildenafil citrate during labour falls short of reducing the incidence of adverse perinatal outcomes potentially related to intrapartum hypoxia, according to a study.

Sildenafil does not improve perinatal outcomes related to hypoxia during labour

18 Jun 2025

Dual-target vaccine for flu, COVID-19 compares favourably with standalone comparators

18 Jun 2025 by

The investigational influenza–COVID-19 combination vaccine mRNA-1083 has demonstrated noninferiority to recommended standard-care flu and COVID-19 vaccines, with higher immune responses and an acceptable safety profile in adults at least 50 years of age, according to the results of a phase III trial.

Dual-target vaccine for flu, COVID-19 compares favourably with standalone comparators

18 Jun 2025

First-line methotrexate on par with prednisone for sarcoidosis

18 Jun 2025 by

The use of methotrexate as a first line of treatment for patients with pulmonary sarcoidosis delivers similar efficacy to prednisone as measured by forced vital capacity after 24 weeks, results of the PREDMETH trial have shown.

First-line methotrexate on par with prednisone for sarcoidosis

18 Jun 2025

Inclisiran superior to ezetimibe in LDL-C reduction in patients without ASCVD

18 Jun 2025

Treatment with inclisiran monotherapy demonstrates good tolerability and better reduction in low-density lipoprotein cholesterol (LDL-C) levels when compared with ezetimibe and placebo in patients without atherosclerotic cardiovascular disease (ASCVD), reports a study.

Inclisiran superior to ezetimibe in LDL-C reduction in patients without ASCVD

18 Jun 2025

RSV-ARI nearly triples mortality risk in new study

18 Jun 2025 by

Acute respiratory infection caused by respiratory syncytial virus (RSV-ARI) nearly triples the risk of death, particularly among individuals with chronic underlying respiratory conditions, as shown in a nationwide cohort study in Denmark.

RSV-ARI nearly triples mortality risk in new study

18 Jun 2025

Adalimumab delivers consistent benefit in plaque psoriasis, with or without methotrexate

18 Jun 2025

Treatment outcomes with adalimumab for plaque psoriasis appear to be similar between patients on monotherapy and those receiving concomitant methotrexate, according to the BSTOP study.

Adalimumab delivers consistent benefit in plaque psoriasis, with or without methotrexate

18 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Long-term odevixibat shows sustained benefits in ALGS

Long-term odevixibat shows sustained benefits in ALGS

How does finerenone fare among DKD patients in real life?

How does finerenone fare among DKD patients in real life?

Abbreviated vs prolonged DAPT: Is shorter better for at-risk patients?

Abbreviated vs prolonged DAPT: Is shorter better for at-risk patients?

Semaglutide helps overweight schizophrenia patients on clozapine lose weight safely

Semaglutide helps overweight schizophrenia patients on clozapine lose weight safely

Sildenafil does not improve perinatal outcomes related to hypoxia during labour

Sildenafil does not improve perinatal outcomes related to hypoxia during labour

Dual-target vaccine for flu, COVID-19 compares favourably with standalone comparators

Dual-target vaccine for flu, COVID-19 compares favourably with standalone comparators

First-line methotrexate on par with prednisone for sarcoidosis

First-line methotrexate on par with prednisone for sarcoidosis

Inclisiran superior to ezetimibe in LDL-C reduction in patients without ASCVD

Inclisiran superior to ezetimibe in LDL-C reduction in patients without ASCVD

RSV-ARI nearly triples mortality risk in new study

RSV-ARI nearly triples mortality risk in new study

Adalimumab delivers consistent benefit in plaque psoriasis, with or without methotrexate

Adalimumab delivers consistent benefit in plaque psoriasis, with or without methotrexate